AndroBioSys

About:

AndroBioSys is a biotechnology company that focuses on the development of novel treatments for prostate disease.

Top Investors: Excell Partners, Erie County Industrial Development Agency, Western New York Venture Association

Description:

AndroBioSys, Inc. (ABS), is a biotechnology company dedicated to the development of novel treatments for prostate disease. Based on technologies developed at Roswell Park Cancer Institute, AndroBioSys is pioneering new approaches to make treatment of prostate cancer curative, not palliative. Preventing progression of prostate disease is intertwined intimately with disruption of the androgen axis. ABS performs contract research screening services for academic, biotechnology and pharmaceutical clients and develops collaborative partnerships to discover new drugs to proprietary prostate disease targets.

Total Funding Amount:

$500000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New York, New York, United States

Founded Date:

2005-01-01

Founders:

Gary J. Smith, James L. Mohler

Number of Employees:

1-10

Last Funding Date:

2009-01-09

IPO Status:

Private

Industries: